ClinicalTrials.gg
CompletedNCT00807885INFUSE-ATUpdated Oct 26, 2011Results posted

Study of Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase

A Phase 4 interventional study of hylenex-facilitated subcutaneous Lactated Ringer's infusion in Dehydration, sponsored by Baxter Healthcare Corporation. Completed at 2 sites in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-10-26.

Sponsored by Baxter Healthcare Corporation · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 87 studies in Dehydration with a site in United States — 7 open to participants now, 8 under way, none of them phase 3. Dehydration · United States.

Enrollment
13th of 74
100 · median 30
Started
2008
with 1 other
Phase 4
6 of 87
none open now
Registered
8th of 87
by date
Lead sponsor
3 of 87
Baxter Healthcare Corporation

Among the 87 studies in Dehydration with a site in United States, this one is the 13th largest by enrollment of the 74 interventional ones that give a count, is one of 2 that started in 2008, is one of 6 in phase 4, and was the 8th registered.

Dehydration

201 studies on the registry are indexed under Dehydration; 28 are open to participants now.

Browse Dehydration studies →

Open to participants now

7 of the 87 studies in Dehydration with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 15 Dehydration studies recruiting now, 7 (47%) set no upper age limit and 7 (47%) stop at 75 or younger; 2 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Dehydration with a site in United States, or all of them as a file.
02

Study summary

The purpose is to evaluate the ease of use and technical challenges encountered during subcutaneous infusion of Lactated Ringer's (LR) solution, preceded by recombinant human hyaluronidase (hylenex), utilizing commonly used angiocatheter gauges and button delivery systems. The safety and tolerability of hylenex-augmented SC infusion of LR through these delivery systems is also being evaluated.

03

Conditions studied

  • Dehydration

Browse trials for

Keywords

  • dehydration
  • fluid therapy
  • hyaluronoglucosaminidase
  • hyaluronidase
  • hypodermoclysis
  • clysis
  • subcutaneous hydration
  • subcutaneous rehydration
  • hyaluronan
  • rHuPH20
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male or female, aged 18 to 60 years
  • intact normal skin without potentially obscuring features on both anterior thighs in the area intended for infusion
  • agreeing to no fluid intake for 12 hours prior to start of study infusion
  • vital signs within normal range or, if outside normal range, deemed not
  • metabolic panel, hematology, virology and standard 10-test urine dipstick tests within normal range, or if outside normal range, deemed not clinically significant
  • if female of ,negative serum pregnancy tests
  • negative urine drug screens
  • written for participation

Exclusion criteria

Exclusion Criteria:

  • lower extremity edema
  • lower extremity pathology that could interfere with study outcome
  • history of cardiovascular disease
  • rales on lung auscultation
  • known allergy to hyaluronidase or other ingredient in the formulation of hylenex
  • pregnancy or breast-feeding a child
  • exposure to any experimental drug within 30 days prior to study participation
  • previous participation in this study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Tegaderm-secured 24 ga Teflon catheter

    subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, Teflon angiocatheter secured with Tegaderm

    Drug: hylenex-facilitated subcutaneous Lactated Ringer's infusion

  • Experimental
    Tape-secured 24 ga Teflon catheter

    subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, Teflon angiocatheter secured with a tape double chevron

    Drug: hylenex-facilitated subcutaneous Lactated Ringer's infusion

  • Experimental
    Tegaderm-secured 24 ga polyurethane catheter

    subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, polyurethane angiocatheter secured with Tegaderm

    Drug: hylenex-facilitated subcutaneous Lactated Ringer's infusion

  • Experimental
    Tape-secured 24 ga polyurethane catheter

    subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, polyurethane angiocatheter secured with a tape double chevron

    Drug: hylenex-facilitated subcutaneous Lactated Ringer's infusion

  • Experimental
    Tegaderm-secured 20 ga Teflon catheter

    subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, Teflon angiocatheter secured with Tegaderm

    Drug: hylenex-facilitated subcutaneous Lactated Ringer's infusion

  • Experimental
    Tape-secured 20 ga Teflon catheter

    subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, Teflon angiocatheter secured with a tape double chevron

    Drug: hylenex-facilitated subcutaneous Lactated Ringer's infusion

  • Experimental
    Tegaderm-secured 20 ga polyurethane catheter

    subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, polyurethane angiocatheter secured with Tegaderm

    Drug: hylenex-facilitated subcutaneous Lactated Ringer's infusion

  • Experimental
    Tape-secured 20 ga polyurethane catheter

    subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, polyurethane angiocatheter secured with a tape double chevron

    Drug: hylenex-facilitated subcutaneous Lactated Ringer's infusion

  • Experimental
    SC button with 27 ga X 9 mm needle

    subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a button-type subcutaneous delivery system (with a 27-gauge, 9 mm long metal needle)

    Drug: hylenex-facilitated subcutaneous Lactated Ringer's infusion

Interventions

06

What researchers measure

Primary outcomes

  1. Technical Challenges

    Protocol-specified challenges encountered during subcutaneous (SC) hylenex administration and/or SC infusion of Lactated Ringer's solution, including SC catheter kinking, catheter/button dislodgement, catheter/button pull-out, infusion pump alarm, other pump failure, healthcare provider intervention to secure/maintain SC infusion eg, re-taping, catheter/button manipulation, etc, and any other type of technical challenge encountered

    Time frame: throughout subcutaneous hylenex and fluid administration period (continuous)

Secondary outcomes

  1. Attempts Needed to Successfully Place Subcutaneous Catheter/Button

    Time frame: from start of first attempt until completion of catheter/button placement

  2. Time Needed to Successfully Place Subcutaneous Catheter/Button

    Time frame: from start of first attempt until completion of catheter/button placement

  3. Time Required to Infuse 1000 mL Fluid

    Time frame: from start of Lactated Ringer's (LR) infusion until 1000 mL LR infused

07

Results

Posted Oct 18, 2011

Participant flow

Participant flow — Overall Study
MilestoneTegaderm-secured 24 ga Teflon CatheterTape-secured 24 ga Teflon CatheterTegaderm-secured 24 ga Polyurethane CatheterTape-secured 24 ga Polyurethane CatheterTegaderm-secured 20 ga Teflon CatheterTape-secured 20 ga Teflon CatheterTegaderm-secured 20 ga Polyurethane CatheterTape-secured 20 ga Polyurethane CatheterSC Button With 27 ga X 9 mm Needle
Started101111101212121111
Completed101111101211121111
Not completed000001000
Withdrew: Lost to follow-up000001000

Outcome measures

PrimaryTechnical Challenges

Protocol-specified challenges encountered during subcutaneous (SC) hylenex administration and/or SC infusion of Lactated Ringer's solution, including SC catheter kinking, catheter/button dislodgement, catheter/button pull-out, infusion pump alarm, other pump failure, healthcare provider intervention to secure/maintain SC infusion eg, re-taping, catheter/button manipulation, etc, and any other type of technical challenge encountered

Time frame:
throughout subcutaneous hylenex and fluid administration period (continuous)
Reported as:
Number · participants
Technical Challenges
participantsTegaderm-secured 24 ga Teflon CatheterTape-secured 24 ga Teflon CatheterTegaderm-secured 24 ga Polyurethane CatheterTape-secured 24 ga Polyurethane CatheterTegaderm-secured 20 ga Teflon CatheterTape-secured 20 ga Teflon CatheterTegaderm-secured 20 ga Polyurethane CatheterTape-secured 20 ga Polyurethane CatheterSC Button With 27 ga X 9 mm Needle
Subjects with at Least One Technical Challenge232222323
Subjects with No Technical Challenges88981010998
Subjects with 1 TEchnical Challenge232122303
Subjects with 2 Technical Challenges000000020
Subjects with 3 Technical Challenges000100000
Subjects with Catheter Kinking010200020
Subjects with Catheter Dislodgement000100000
Subjects with Catheter Pulled Out000000010
Subjects with Infusion Pump Alarm222122313
Subjects with Infusion Pump Failure000000000
SecondaryAttempts Needed to Successfully Place Subcutaneous Catheter/Button
Time frame:
from start of first attempt until completion of catheter/button placement
Reported as:
Number · participants
Attempts Needed to Successfully Place Subcutaneous Catheter/Button
participantsTegaderm-secured 24 ga Teflon CatheterTape-secured 24 ga Teflon CatheterTegaderm-secured 24 ga Polyurethane CatheterTape-secured 24 ga Polyurethane CatheterTegaderm-secured 20 ga Teflon CatheterTape-secured 20 ga Teflon CatheterTegaderm-secured 20 ga Polyurethane CatheterTape-secured 20 ga Polyurethane CatheterSC Button With 27 ga X 9 mm Needle
1 Attempt101110101211121111
2 Attempts001001000
SecondaryTime Needed to Successfully Place Subcutaneous Catheter/Button
Time frame:
from start of first attempt until completion of catheter/button placement
Reported as:
Median · seconds
Time Needed to Successfully Place Subcutaneous Catheter/Button
secondsTegaderm-secured 24 ga Teflon CatheterTape-secured 24 ga Teflon CatheterTegaderm-secured 24 ga Polyurethane CatheterTape-secured 24 ga Polyurethane CatheterTegaderm-secured 20 ga Teflon CatheterTape-secured 20 ga Teflon CatheterTegaderm-secured 20 ga Polyurethane CatheterTape-secured 20 ga Polyurethane CatheterSC Button With 27 ga X 9 mm Needle
Time Needed to Successfully Place Subcutaneous Catheter/Button23 (1 to 39)43 (2 to 84)30 (2 to 63)34 (10 to 96)30 (2 to 58)49 (2 to 133)31 (1 to 90)15 (1 to 96)9 (1 to 47)
SecondaryTime Required to Infuse 1000 mL Fluid
Time frame:
from start of Lactated Ringer's (LR) infusion until 1000 mL LR infused
Reported as:
Mean · hours
Time Required to Infuse 1000 mL Fluid
hoursTegaderm-secured 24 ga Teflon CatheterTape-secured 24 ga Teflon CatheterTegaderm-secured 24 ga Polyurethane CatheterTape-secured 24 ga Polyurethane CatheterTegaderm-secured 20 ga Teflon CatheterTape-secured 20 ga Teflon CatheterTegaderm-secured 20 ga Polyurethane CatheterTape-secured 20 ga Polyurethane CatheterSC Button With 27 ga X 9 mm Needle
Time Required to Infuse 1000 mL Fluid6.82 ± 0.0586.78 ± 0.0986.81 ± 0.0136.80 ± 0.1146.78 ± 0.0716.80 ± 0.0136.81 ± 0.0786.79 ± 0.1086.82 ± 0.078

Adverse events

Collected over 6 d post-treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tegaderm-secured 24 ga Teflon Catheter—0/10 (0%)6/10 (60%)
Tape-secured 24 ga Teflon Catheter—0/11 (0%)5/11 (45.5%)
Tegaderm-secured 24 ga Polyurethane Catheter—0/11 (0%)9/11 (81.8%)
Tape-secured 24 ga Polyurethane Catheter—0/10 (0%)7/10 (70%)
Tegaderm-secured 20 ga Teflon Catheter—1/12 (8.3%)9/12 (75%)
Tape-secured 20 ga Teflon Catheter—0/12 (0%)10/12 (83.3%)
Tegaderm-secured 20 ga Polyurethane Catheter—0/12 (0%)10/12 (83.3%)
Tape-secured 20 ga Polyurethane Catheter—0/11 (0%)10/11 (90.9%)
SC Button With 27 ga X 9 mm Needle—0/11 (0%)8/11 (72.7%)
Most frequent serious events
Most frequent serious events
EventTegaderm-secured 24 ga Teflon CatheterTape-secured 24 ga Teflon CatheterTegaderm-secured 24 ga Polyurethane CatheterTape-secured 24 ga Polyurethane CatheterTegaderm-secured 20 ga Teflon CatheterTape-secured 20 ga Teflon CatheterTegaderm-secured 20 ga Polyurethane CatheterTape-secured 20 ga Polyurethane CatheterSC Button With 27 ga X 9 mm Needle
calculus uretericRenal and urinary disorders0/100/110/110/101/120/120/120/110/11
Most frequent other events
Most frequent other events
EventTegaderm-secured 24 ga Teflon CatheterTape-secured 24 ga Teflon CatheterTegaderm-secured 24 ga Polyurethane CatheterTape-secured 24 ga Polyurethane CatheterTegaderm-secured 20 ga Teflon CatheterTape-secured 20 ga Teflon CatheterTegaderm-secured 20 ga Polyurethane CatheterTape-secured 20 ga Polyurethane CatheterSC Button With 27 ga X 9 mm Needle
Infusion site painGeneral disorders2/104/114/113/106/129/128/128/113/11
Infusion site erythemaGeneral disorders3/102/114/112/102/123/122/124/113/11
Infusion site swellingGeneral disorders0/101/111/112/103/124/123/120/111/11
Pain in extremityMusculoskeletal and connective tissue disorders2/101/110/113/101/122/120/120/112/11
HeadacheNervous system disorders1/100/111/110/101/121/120/122/110/11

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Tegaderm-secured 24 ga Teflon CatheterTape-secured 24 ga Teflon CatheterTegaderm-secured 24 ga Polyurethane CatheterTape-secured 24 ga Polyurethane CatheterTegaderm-secured 20 ga Teflon CatheterTape-secured 20 ga Teflon CatheterTegaderm-secured 20 ga Polyurethane CatheterTape-secured 20 ga Polyurethane CatheterSC Button With 27 ga X 9 mm NeedleTotal
<=18 years0000000000
Between 18 and 65 years101111101212121111100
>=65 years0000000000
Age Continuous
Age Continuous(years)Tegaderm-secured 24 ga Teflon CatheterTape-secured 24 ga Teflon CatheterTegaderm-secured 24 ga Polyurethane CatheterTape-secured 24 ga Polyurethane CatheterTegaderm-secured 20 ga Teflon CatheterTape-secured 20 ga Teflon CatheterTegaderm-secured 20 ga Polyurethane CatheterTape-secured 20 ga Polyurethane CatheterSC Button With 27 ga X 9 mm NeedleTotal
Mean34.6 ± 9.3936.0 ± 10.633.8 ± 10.435.3 ± 10.934.0 ± 12.534.3 ± 10.333.6 ± 10.732.4 ± 12.736.6 ± 12.334.5 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)Tegaderm-secured 24 ga Teflon CatheterTape-secured 24 ga Teflon CatheterTegaderm-secured 24 ga Polyurethane CatheterTape-secured 24 ga Polyurethane CatheterTegaderm-secured 20 ga Teflon CatheterTape-secured 20 ga Teflon CatheterTegaderm-secured 20 ga Polyurethane CatheterTape-secured 20 ga Polyurethane CatheterSC Button With 27 ga X 9 mm NeedleTotal
Female31833654538
Male710379677662
Region of Enrollment
Region of Enrollment(participants)Tegaderm-secured 24 ga Teflon CatheterTape-secured 24 ga Teflon CatheterTegaderm-secured 24 ga Polyurethane CatheterTape-secured 24 ga Polyurethane CatheterTegaderm-secured 20 ga Teflon CatheterTape-secured 20 ga Teflon CatheterTegaderm-secured 20 ga Polyurethane CatheterTape-secured 20 ga Polyurethane CatheterSC Button With 27 ga X 9 mm NeedleTotal
United States101111101212121111100
08

Study locations

2 sites
  • MDS Pharma Services
    Lincoln, Nebraska 68502, United States
  • MDS Pharma Services
    Neptune, New Jersey 07753, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2011, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2008
First posted
Dec 12, 2008
Start
Dec 2008
Primary completionActual
Jan 2009
CompletionActual
Jan 2009
Results first posted
Oct 18, 2011
Last update
Oct 26, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00807885
Responsible party
Sponsor
First posted
Dec 12, 2008
Start date
Dec 2008
Primary completion
Jan 2009
Completion
Jan 2009
Results posted
Oct 18, 2011
Last update
Oct 26, 2011

Study contacts

George Harb, MD, MPH
study director · Baxter Healthcare Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hyaluronidase (human recombinant)

Start the discussion